108 related articles for article (PubMed ID: 24485306)
1. Hypermethylation of RAD51L3 and XRCC2 genes to predict late toxicity in chemoradiotherapy-treated cervical cancer patients.
Paulíková S; Chmelařová M; Petera J; Palička V; Paulík A
Folia Biol (Praha); 2013; 59(6):240-5. PubMed ID: 24485306
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation.
Sood S; Patel FD; Ghosh S; Arora A; Dhaliwal LK; Srinivasan R
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):720-7. PubMed ID: 26344356
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation of p73 and p53 genes in cervical cancer patients among north Indian population.
Jha AK; Nikbakht M; Jain V; Sehgal A; Capalash N; Kaur J
Mol Biol Rep; 2012 Sep; 39(9):9145-57. PubMed ID: 22729911
[TBL] [Abstract][Full Text] [Related]
4. Interplay between promoter methylation and chromosomal loss in gene silencing at 3p11-p14 in cervical cancer.
Lando M; Fjeldbo CS; Wilting SM; C Snoek B; Aarnes EK; Forsberg MF; Kristensen GB; Steenbergen RD; Lyng H
Epigenetics; 2015; 10(10):970-80. PubMed ID: 26291246
[TBL] [Abstract][Full Text] [Related]
5. [Correlation between DNA Methylation of ZNF772 Promoter Region and Cervical Cancer].
Li M; Li O; Sun J; Zheng X; Ma D
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2020 Apr; 42(2):164-171. PubMed ID: 32385021
[No Abstract] [Full Text] [Related]
6. ATM and TGFB1 genes polymorphisms in prediction of late complications of chemoradiotherapy in patients with locally advanced cervical cancer.
Paulikova S; Petera J; Sirak I; Vosmik M; Drastikova M; Dusek L; Cvanova M; Soumarova R; Spacek J; Beranek M
Neoplasma; 2014; 61(1):70-6. PubMed ID: 24195511
[TBL] [Abstract][Full Text] [Related]
7. Status of p16(INK4a) and E-cadherin gene promoter methylation in Moroccan patients with cervical carcinoma.
Attaleb M; El hamadani W; Khyatti M; Benbacer L; Benchekroun N; Benider A; Amrani M; El Mzibri M
Oncol Res; 2009; 18(4):185-92. PubMed ID: 20112504
[TBL] [Abstract][Full Text] [Related]
8. Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression.
Iliopoulos D; Oikonomou P; Messinis I; Tsezou A
Oncol Rep; 2009 Jul; 22(1):199-204. PubMed ID: 19513524
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.
Yang WT; Zheng PS
PLoS One; 2014; 9(2):e88827. PubMed ID: 24551169
[TBL] [Abstract][Full Text] [Related]
10. Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach.
Pavicic W; Perkiö E; Kaur S; Peltomäki P
Mol Med; 2011; 17(7-8):726-35. PubMed ID: 21327300
[TBL] [Abstract][Full Text] [Related]
11. Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.
Chmelařová M; Křepinská E; Spaček J; Laco J; Nekvindová J; Palička V
Folia Biol (Praha); 2012; 58(6):246-50. PubMed ID: 23438850
[TBL] [Abstract][Full Text] [Related]
12. Associations of MGMT promoter hypermethylation with squamous intraepithelial lesion and cervical carcinoma: A meta-analysis.
Huang J; Luo JY; Tan HZ
PLoS One; 2019; 14(10):e0222772. PubMed ID: 31574102
[TBL] [Abstract][Full Text] [Related]
13. A COMPARATIVE ANALYSIS OF METHYLATION STATUS OF TUMOR SUPPRESSOR GENES IN PAIRED BIOPSY AND SERUM SAMPLES FROM CERVICAL CANCER PATIENTS AMONG NORTH INDIAN POPULATION.
Jha AK; Sharma V; Nikbakht M; Jain V; Sehgal A; Capalash N; Kaur J
Genetika; 2016 Feb; 52(2):255-9. PubMed ID: 27215041
[TBL] [Abstract][Full Text] [Related]
14. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
15. Outcome of international Federation of gynecology and obstetrics stage IIb cervical cancer from 2003 to 2012: an evaluation of treatments and prognosis: a retrospective study.
Guo L; Liu X; Wang L; Sun H; Huang K; Li X; Tang F; Li S; Yuan X; Wang C
Int J Gynecol Cancer; 2015 Jun; 25(5):910-8. PubMed ID: 25867278
[TBL] [Abstract][Full Text] [Related]
16. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation in serum and tumors of cervical cancer patients.
Widschwendter A; Müller HM; Fiegl H; Ivarsson L; Wiedemair A; Müller-Holzner E; Goebel G; Marth C; Widschwendter M
Clin Cancer Res; 2004 Jan; 10(2):565-71. PubMed ID: 14760078
[TBL] [Abstract][Full Text] [Related]
18. Detection of methylation of the promoter region of the MAL and CADM1 genes by pyrosequencing in cervical carcinoma.
Mersakova S; Visnovsky J; Holubekova V; Nachajova M; Kudela E; Danko J; Lasabova Z
Neuro Endocrinol Lett; 2014; 35(7):619-23. PubMed ID: 25617886
[TBL] [Abstract][Full Text] [Related]
19. A global profile of gene promoter methylation in treatment-naïve urothelial cancer.
Ibragimova I; Dulaimi E; Slifker MJ; Chen DY; Uzzo RG; Cairns P
Epigenetics; 2014 May; 9(5):760-73. PubMed ID: 24521710
[TBL] [Abstract][Full Text] [Related]
20. The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer.
Jung S; Yi L; Jeong D; Kim J; An S; Oh TJ; Kim CH; Kim CJ; Yang Y; Kim KI; Lim JS; Lee MS
Oncol Rep; 2011 Jan; 25(1):245-52. PubMed ID: 21109983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
